US Patent Issued to Incyte on July 15 for "Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof" (German Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,983, issued on July 15, was assigned to Incyte Corp. (Wilmington, Del.).

"Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof" was invented by Jan Endell (Munich), Konstantin Petropoulos (Munich), Peter Kelemen (Munich), Rainer Boxhammer (Aying, Germany) and Markus Ruckert (Kottgeisering, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia."

The patent was filed on Oct. 27, 2017, under Application No. 16/342,...